ACTU today
$0.30-$0.01 (-2.05%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bearish
5 minLeaning Bearish
Daily trend turns up above $0.96
Key levels
Resistance$0.60
Resistance$0.41
Latest news & SEC filings
ProductActuate Therapeutics Reports Lab Findings on Elraglusib in Melanoma
LegalActuate Therapeutics gets U.S. patent allowance for Elraglusib oral tablets
ProductAllowed patent application covers oral elraglusib tablet, Actuate Therapeutics reports
SEC FilingActuate Therapeutics, Inc. filed an insider trading report (Form 4)
All ACTU news →About Actuate Therapeutics
Actuate Therapeutics is a clinical-stage drug developer creating treatments for hard-to-treat tumors by blocking a specific enzyme involved in cancer cell signaling. Its main candidate, elraglusib, is a small molecule given both by infusion and as a pill. The company targets pancreatic cancer, certain childhood solid tumors, melanoma, and colorectal and lung cancers, and it operates mainly in the United States.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
ACTUATE THERAPEUTICS, INC. (ACTU)
What Is the Price Target for ACTU?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ACTU a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ACTU.
Start Free Trial →Is ACTU Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B
Fair Value
$0.50
12
Moat Score
NONE
4/9
Piotroski Score
-19.1
Altman Z-Score
What Is Smart Money Doing with ACTU?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
UNCHANGED
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SCHMITT DANIEL M | director officer | Buy | 140,844 | $50K | Oct 28, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ACTU Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
67.48%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for ACTU
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ACTU, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:50:51 | $0.30 | 1,510 | $$450 | MIDPOINT |
| 20:37:27 | $0.30 | 1,004 | $$296 | SELL |
| 20:30:46 | $0.30 | 1,958 | $$592 | SELL |
| 19:04:06 | $0.31 | 24,380 | $$8K | BUY |
| 19:04:06 | $0.31 | 21,220 | $$7K | BUY |
5 dark pool trades shown · $$15K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ACTUATE THERAPEUTICS, INC. (ACTU) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ACTU — frequently asked questions
What is ACTU stock price today?
ACTUATE THERAPEUTICS, INC. (ACTU) is at $0.30, down 2.05% (-$0.01) at the Nov 12, 2026 close.
Why is ACTU stock moving today?
Latest ACTU news — Nov 5, 2026: Actuate Therapeutics Reports Lab Findings on Elraglusib in Melanoma · Nov 2, 2026: Actuate Therapeutics gets U.S. patent allowance for Elraglusib oral tablets
What do analysts rate ACTU?
Analyst ratings for ACTU: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did ACTU beat earnings?
ACTU last reported on Aug 13, 2026: EPS -$0.20 vs -$0.20 expected — a beat of 1.6%.
Does ACTU pay a dividend?
ACTU does not currently pay a dividend.
What are ACTU support and resistance levels?
Resistance: $0.41, $0.60, $0.71.
What are insiders doing with ACTU?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on ACTU?
Nov 5, 2026: Actuate Therapeutics Reports Lab Findings on Elraglusib in Melanoma · Nov 2, 2026: Actuate Therapeutics gets U.S. patent allowance for Elraglusib oral tablets · Nov 2, 2026: Allowed patent application covers oral elraglusib tablet, Actuate Therapeutics reports